600196 复星医药
已收盘 12-05 15:00:00
资讯
新帖
简况
复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权
中金财经 · 12-04 15:36
复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权
复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市
证券之星 · 12-03 16:56
复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市
复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人
中金财经 · 12-03
复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人
复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%
证券之星 · 12-02
复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%
复星医药 - 含肝素钠注射液的药物申请已被NMPA接受
美股速递 · 12-02
复星医药 - 含肝素钠注射液的药物申请已被NMPA接受
复星医药(02196)：刘毅获选举为执行董事
智通财经 · 12-02
复星医药(02196)：刘毅获选举为执行董事
复星医药子公司HLX14药品注册申请获受理
财中社 · 12-02
复星医药子公司HLX14药品注册申请获受理
复星医药子公司肝素钠注射液注册申请获国家药监局受理
财中社 · 12-02
复星医药子公司肝素钠注射液注册申请获国家药监局受理
复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准
智通财经 · 12-01
复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准
复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%
证券之星 · 11-28
复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%
复星医药与睿智医药达成战略合作
人民财讯 · 11-25
复星医药与睿智医药达成战略合作
复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理
智通财经 · 11-21
复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理
复星医药(600196.SH)：斯鲁利单抗纳入突破性治疗药物程序 全球范围内尚无靶向PD-1的单抗药品获批用于胃癌新辅助/辅助治疗
智通财经 · 11-20
复星医药(600196.SH)：斯鲁利单抗纳入突破性治疗药物程序 全球范围内尚无靶向PD-1的单抗药品获批用于胃癌新辅助/辅助治疗
复星医药(600196.SH)：复方聚乙二醇(3350)电解质散药品注册申请获受理
智通财经 · 11-18
复星医药(600196.SH)：复方聚乙二醇(3350)电解质散药品注册申请获受理
每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准
证券之星 · 11-16
每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准
复星医药(600196.SH)控股子公司药品获美国FDA注册批准
智通财经 · 11-14
复星医药(600196.SH)控股子公司药品获美国FDA注册批准
复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市
复星医药官微 · 11-12
复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市
与复星医药“分手”后，真实生物第三次冲击港股IPO
深圳商报 · 11-11
与复星医药“分手”后，真实生物第三次冲击港股IPO
复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%
证券之星 · 11-08
复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%
复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%
证券之星 · 11-06
复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.14,"timestamp":1764918000000,"preClose":26.97,"halted":0,"volume":10041311,"delay":0,"changeRate":0.0063,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"已收盘","change":0.17,"latestTime":"12-05 15:00:00","open":27.03,"high":27.18,"low":26.69,"amount":271000000,"amplitude":0.0182,"askPrice":27.15,"askSize":172,"bidPrice":27.14,"bidSize":727,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":26.97,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":29.67,"lowLimit":24.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.51,"roa":"--","peRate":22.077605,"roe":"5.3%","epsLYR":1.04,"committee":0.318431,"marketValue":72475000000,"turnoverRate":0.0047,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-08。","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":21.48,"timestamp":1764922148002,"preClose":21.26,"halted":0,"volume":1731511,"delay":0,"premium":"-28.14"},"floatMarketCap":57496000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2588009934","title":"复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009934","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009934?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:36","pubTimestamp":1764833770,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月3日发布公告，宣布其2025年A股股票期权激励计划首次授予的登记工作已完成。本次激励计划首次授予的授予日为2025年11月4日，实际向182名激励对象授予了总计4,446,400份A股股票期权，约占公司当前总股本的0.1665%。 根据激励计划安排，首次授予的A股期权将分三期行权，等待期分别为12个月、24个月和36个月。 本次股权激励产生的股份支付费用将在激励计划实施过程中分期摊销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31844205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","600196","BK0060","BK0096","BK0183","BK0188","BK0239","BK0175","02196","BK0028","BK0187","BK1593","BK1191","BK0196","159982","399300","BK1515"],"gpt_icon":0},{"id":"2588197860","title":"复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588197860","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588197860?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:56","pubTimestamp":1764752215,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海复星医药产业发展有限公司（简称“复星医药产业”）收到国家药品监督管理局关于同意FXS887片（简称“FXS0887”）用于晚期恶性实体瘤开展临床试验的批准。FXS0887为本集团（即本公司及控股子公司/单位）自主研发的口服小分子创新药物，拟用于治疗晚期恶性实体瘤。截至本公告日期（即2025年12月3日），于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0183","BK0028","BK1191","159992","600196","BK0188","BK0012","BK1515","02196","BK0096","BK0175","06978","BK1593","BK0239","BK0196","BK0187","BK1161","BK1574"],"gpt_icon":0},{"id":"2588067851","title":"复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588067851","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588067851?lang=zh_cn&edition=full","pubTime":"2025-12-03 07:58","pubTimestamp":1764719922,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月2日发布公告，披露其参与设立的私募股权投资基金——大连星未来创业创新基金合伙企业发生有限合伙人变更。变更完成后，大连金运将持有基金29%的份额，成为新的有限合伙人。复星医药通过控股子公司大连复健和宁波复瀛合计认缴的2.55亿元出资额及51%的份额比例保持不变，基金总认缴规模仍为5亿元。大连金运由大连市财政局全资控股，与复星医药无关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31839848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","600196","BK0239","BK0187","BK0012","BK0060","BK0188","BK1191","BK0096","BK0183","02196","BK1515","BK0175","BK0028","BK1593"],"gpt_icon":0},{"id":"2588805956","title":"复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588805956","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588805956?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:08","pubTimestamp":1764684535,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，复星医药报收于27.09元，较前一交易日下跌0.88%，最新总市值为723.42亿元。该股当日开盘27.35元，最高27.35元，最低27.0元，成交额达2.65亿元，换手率为0.46%。公司近日发布公告称，上海复星医药（集团）股份有限公司于2025年12月2日召开2025年第二次临时股东会，会议由董事会召集，董事长陈玉卿主持，采用现场与网络结合方式召开。出席会议股东共1,726人，代表有表决权股份总数1,081,006,672股，占公司总股本的40.9541%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"1128708003","title":"复星医药 - 含肝素钠注射液的药物申请已被NMPA接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1128708003","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128708003?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:46","pubTimestamp":1764679594,"startTime":"0","endTime":"0","summary":"复星医药 - 含肝素钠注射液的药物申请已被NMPA接受","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0183","BK0060","BK0188","BK0196","BK0028","600196","BK0187","BK0012","BK0239","BK0175"],"gpt_icon":0},{"id":"2588370540","title":"复星医药(02196)：刘毅获选举为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2588370540","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588370540?lang=zh_cn&edition=full","pubTime":"2025-12-02 19:47","pubTimestamp":1764676050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于临时股东会上，刘毅先生获股东正式选举为第十届董事会执行董事，委任自2025年12月2日起生效至本届董事会任期届满为止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0175","BK1593","BK0196","BK0096","BK0012","BK0188","BK0028","BK1515","02196","600196","BK0060","BK0183","BK1191","BK0239"],"gpt_icon":0},{"id":"2588311400","title":"复星医药子公司HLX14药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588311400","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588311400?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:10","pubTimestamp":1764670224,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14的药品注册申请已获国家药品监督管理局受理。HLX14的适应症参照已在中国境内获批上市的药品普罗力?的所有适应症。HLX14目前已在美国、欧盟和英国获批上市，2024年9月，其在加拿大的上市注册申请也已获受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580475079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0096","BK0188","02196","BK0028","BK0060","BK1191","BK0183","BK0196","600196","BK0175","BK0187","BK1515","BK0239","BK0012"],"gpt_icon":0},{"id":"2588803114","title":"复星医药子公司肝素钠注射液注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803114","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803114?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:06","pubTimestamp":1764669990,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获国家药品监督管理局受理。公告中提到，苏州二叶制药有限公司就肝素钠注射液的药品注册申请获得受理，该药品为公司自主研发的化学药品，主要用于防治静脉血栓和肺栓塞等多种医疗用途。截至2025年10月，苏州二叶在该药品上的累计研发投入约为861万元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580474174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0096","02196","BK0060","BK0188","BK0187","BK1515","BK1191","BK0196","BK1593","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2588728927","title":"复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728927","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728927?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:04","pubTimestamp":1764579890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX37注射液(即重组人源化抗PD-L1与抗VEGF双特异性抗体注射液;简称“HLX37”)用于治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展HLX37的Ⅰ期临床试验。HLX37是集团自主研发的重组人源化抗PD-L1与抗VEGF双特异性抗体，拟用于治疗晚期/转移性实体瘤。截至目前的临床前研究表明，HLX37能够抑制肿瘤生长，且具有良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"2586738565","title":"复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738565?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:13","pubTimestamp":1764339192,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，复星医药报收于27.13元，较前一交易日下跌0.29%，最新总市值为724.49亿元。公司近日发布公告称，上海复星医药（集团）股份有限公司将于2025年12月2日召开2025年第二次临时股东会，会议采用现场投票和网络投票相结合的方式，审议《关于选举执行董事的议案》。股权登记日为2025年11月26日，A股股东可于当日收市后在中国证券登记结算有限责任公司上海分公司登记在册参与投票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"2586474186","title":"复星医药与睿智医药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474186","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586474186?lang=zh_cn&edition=full","pubTime":"2025-11-25 23:01","pubTimestamp":1764082916,"startTime":"0","endTime":"0","summary":"人民财讯11月25日电，11月25日，复星医药与睿智医药在上海举行战略合作框架协议签约仪式。复星医药高级副总裁兼全球研发中心首席执行官李翔表示，未来，借助与睿智医药全链条研发服务能力，有望进一步提升复星医药在多种类型药物研发领域的效率与质量，加速创新成果转化，巩固我们在创新医药领域的竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574517765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0077","02196","BK0216","BK0012","BK0196","BK1515","BK0175","BK0096","BK0188","BK0239","BK0028","BK0187","BK0183","BK1593","BK1191","300149","600196","BK0060"],"gpt_icon":0},{"id":"2585116342","title":"复星医药(600196.SH)子公司芦沃美替尼片药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585116342","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585116342?lang=zh_cn&edition=full","pubTime":"2025-11-21 17:25","pubTimestamp":1763717103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司就复迈宁用于治疗2岁及2岁以上朗格汉斯细胞组织细胞增生症儿童患者的药品注册申请获国家药品监督管理局受理并已被纳入优先审评程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","02196","BK0096","BK0012","BK0060","BK0175","600196","BK0188","BK1593","BK0183","BK0196","BK1515","BK0028","BK1191","BK0239"],"gpt_icon":0},{"id":"2584618171","title":"复星医药(600196.SH)：斯鲁利单抗纳入突破性治疗药物程序 全球范围内尚无靶向PD-1的单抗药品获批用于胃癌新辅助/辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2584618171","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584618171?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:57","pubTimestamp":1763629023,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 复星医药(600196.SH)发布公告，根据国家药品监督管理局(以下简称“国家药监局”)药品审评中心公示信息，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的斯鲁利单抗注射液(中国境内1商品名：汉斯状®;以下简称“该药品”)用于联合化疗新辅助/辅助治疗胃癌(GCneo)已被纳入突破性治疗药物程序。该药品为集团自主研发的创新型抗 PD-1 单抗。截至本公告日期，全球范围内尚无靶向PD-1的单克隆抗体药品获批用于胃癌新辅助/辅助治疗。根据IQVIA MIDAS™最新数据，2024年，靶向PD-1的单克隆抗体药品于全球的销售额约为457.04亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1191","600196","BK1515","LU1169590202.USD","BK0028","BK0188","BK0175","02196","BK0060","BK0196","LU1169589451.USD","BK0183","PD","BK0239","BK0012","BK0096","BK1593","BK4023"],"gpt_icon":0},{"id":"2584982193","title":"复星医药(600196.SH)：复方聚乙二醇(3350)电解质散药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2584982193","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584982193?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:32","pubTimestamp":1763454771,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 复星医药(600196.SH)发布公告，近日，公司控股子公司上海朝晖药业有限公司就复方聚乙二醇(3350)电解质散(以下简称“该药品”)的药品注册申请获国家药品监督管理局受理。复方聚乙二醇(3350)电解质散系化学药品，拟用于慢性便秘症(器质性疾病引起的便秘除外)。根据IQVIA CHPA最新数据，2024年，复方聚乙二醇电解质散于中国境内(不包括港澳台地区)的销售额约为人民币8.73亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK0183","BK1593","BK0175","BK0060","BK0188","BK0012","BK0196","BK0096","02196","BK1191","BK0239","BK0187","600196","BK0028"],"gpt_icon":0},{"id":"2583659958","title":"每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659958?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:17","pubTimestamp":1763230632,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，复星医药报收于28.82元，较上周的28.23元上涨2.09%。本周，复星医药11月14日盘中最高价报29.13元。本周关注点公司公告汇总：复星医药控股子公司复宏汉霖自主研发的帕妥珠单抗注射液获美国FDA批准上市。复宏汉霖已将该产品在美国等地区的商业化权利授予Organon LLC，将依据协议获得销售里程碑款及销售提成。截至2025年10月，该产品累计研发投入约2.25亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0183","BK0028","BK0196","BK1191","02196","BK0096","BK0012","BK0175","BK0060","BK1515","BK0187","BK1593","600196"],"gpt_icon":0},{"id":"2583576177","title":"复星医药(600196.SH)控股子公司药品获美国FDA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583576177","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583576177?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:06","pubTimestamp":1763111217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的POHERDY1注射液的生物制品许可申请获美国FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0096","BK0196","BK0175","BK0239","02196","BK0183","BK0012","BK0028","BK1191","BK1593","BK0187","BK0188","600196","BK1515"],"gpt_icon":0},{"id":"2582932461","title":"复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2582932461","media":"复星医药官微","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582932461?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:36","pubTimestamp":1762940160,"startTime":"0","endTime":"0","summary":"中国上海，2025年11月11日——复星医药子公司复宏汉霖（2696.HK）宣布，英国药品和健康产品管理局（MHRA）已批准地舒单抗注射液（60 mg/mL）BILDYOS （denosumab）和地舒单抗注射液（120mg/ ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251112/c672428158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0175","BK0239","600196","BK0188","BK0028","BK0187","BK0183","BK0196","BK0060","BK0012","BK0096"],"gpt_icon":0},{"id":"2582331338","title":"与复星医药“分手”后，真实生物第三次冲击港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582331338","media":"深圳商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582331338?lang=zh_cn&edition=full","pubTime":"2025-11-11 12:45","pubTimestamp":1762836300,"startTime":"0","endTime":"0","summary":"据港交所披露，真实生物科技有限公司近日递表交港交所主板，中金公司为其独家保荐人。这是公司第三次在港交所申请上市，此前曾在2022年8月、2025年2月递表过港交所，但最终无果。资料显示， ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251111/c672391030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0187","BK0196","BK0096","BK0175","BK0183","600196","BK0012","BK0028","BK0060","BK0239","BK0188"],"gpt_icon":0},{"id":"2581880404","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581880404?lang=zh_cn&edition=full","pubTime":"2025-11-08 00:23","pubTimestamp":1762532604,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药11月8日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押2000.0万股，占总股本0.75%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份5.47亿股，占其持股总数的61.46%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110800000751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0096","BK0196","BK0175","BK0239","02196","BK0183","BK0012","BK0028","BK1191","BK1593","BK0187","BK0188","600196","BK1515"],"gpt_icon":0},{"id":"2581091141","title":"复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091141?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:14","pubTimestamp":1762438463,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，复星医药报收于28.49元，较前一交易日上涨1.21%，最新总市值为760.81亿元。公司近日发布公告称，上海复星医药（集团）股份有限公司为控股子公司复星医药产业、复星安特金、复星健康及复星曜泓（西藏）提供担保，担保金额分别为20,000万元、30,000万元、20,000万元和32,000万元。截至2025年11月6日，集团实际对外担保余额约2,354,378万元，占2024年末经审计净资产的49.82%，无逾期担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0060","BK0239","BK0012","BK0188","BK1191","600196","BK0028","BK0196","BK1515","BK1593","02196","BK0096","BK0183","BK0175"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764987828275,"stockEarnings":[{"period":"1week","weight":0.0004},{"period":"1month","weight":-0.0359},{"period":"3month","weight":-0.101},{"period":"6month","weight":0.0969},{"period":"1year","weight":0.0511},{"period":"ytd","weight":0.1048}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}